Hepatotoxic reactions during treatment of newly diagnosed patients with pulmonary multiple drug resistant tuberculosis
216 new pulmonary tuberculosis patients suffering from multiple drug resistance (MDR) were examined. The patients were divided into 2 groups. The first group consisted of 164 patients in whom when admitted to hospital, GeneXpert MTB/RIF was used to test the resistance of Mycobacterium tuberculosis (...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | Russian |
Published: |
NEW TERRA Publishing House
2019-08-01
|
Series: | Tuberkulez i Bolezni Lëgkih |
Subjects: | |
Online Access: | https://www.tibl-journal.com/jour/article/view/1311 |
id |
doaj-b85b8381261f40b699c8476af1395d19 |
---|---|
record_format |
Article |
spelling |
doaj-b85b8381261f40b699c8476af1395d192021-07-28T20:57:48ZrusNEW TERRA Publishing HouseTuberkulez i Bolezni Lëgkih2075-12302542-15062019-08-01977212710.21292/2075-1230-2019-97-7-21-271311Hepatotoxic reactions during treatment of newly diagnosed patients with pulmonary multiple drug resistant tuberculosisR. Yu. Аbdullаev0O. G. Komissаrovа1E. S. Chumаkovа2V. S. Odinets3A. E. Ergeshov4Central Tuberculosis Research InstituteCentral Tuberculosis Research Institute; Pirogov Russian National Research Medical UniversityRegional Clinical TB DispensaryRegional Clinical TB DispensaryCentral Tuberculosis Research Institute216 new pulmonary tuberculosis patients suffering from multiple drug resistance (MDR) were examined. The patients were divided into 2 groups. The first group consisted of 164 patients in whom when admitted to hospital, GeneXpert MTB/RIF was used to test the resistance of Mycobacterium tuberculosis (MTB) to rifampicin. Initially, patients in this group were treated with chemotherapy regimen 4 (pyrazinamide, kanamycin/amikacin/capreomycin, fluoroquinolones, cycloserine/terizidone, prothionamide, PAS). Group 2 included 97 patients. They all were treated with chemotherapy regimen 1 (isoniazid, rifampicin, pyrazinamide, ethambutol/streptomycin) before MDR was confirmed in them by sputum culture on solid media (in 2-3 months of treatment) after that treatment regimen was amended with re-registration for chemotherapy regimen 4. It was found out that hepatotoxic reactions in patients without initial abnormal liver function when prescribing chemotherapy regimen 4 occurred in 31.3% of cases and when initially using regimen 1 followed by switching to regimen 4 – in 87.8% of cases ( p < 0.001). In the course of treatment, the signs of liver damage in patients who initially received regimen 4 were more frequent in the first 2 months of treatment, whereas in patients treated initially with regimen 1 with subsequent switching to regimen 4 – during the first 4 months. In the overwhelming majority of cases, hepatotoxic reactions were mild in patients who initially received regimen 4 as well as in patients initially treated with regimen 1 followed by switching to regimen 4. However, severe hepatotoxic reactions were more often observed in patients from Group 2.https://www.tibl-journal.com/jour/article/view/1311newly detected tuberculosismultiple drug resistancehepatotoxic reactionschemotherapy |
collection |
DOAJ |
language |
Russian |
format |
Article |
sources |
DOAJ |
author |
R. Yu. Аbdullаev O. G. Komissаrovа E. S. Chumаkovа V. S. Odinets A. E. Ergeshov |
spellingShingle |
R. Yu. Аbdullаev O. G. Komissаrovа E. S. Chumаkovа V. S. Odinets A. E. Ergeshov Hepatotoxic reactions during treatment of newly diagnosed patients with pulmonary multiple drug resistant tuberculosis Tuberkulez i Bolezni Lëgkih newly detected tuberculosis multiple drug resistance hepatotoxic reactions chemotherapy |
author_facet |
R. Yu. Аbdullаev O. G. Komissаrovа E. S. Chumаkovа V. S. Odinets A. E. Ergeshov |
author_sort |
R. Yu. Аbdullаev |
title |
Hepatotoxic reactions during treatment of newly diagnosed patients with pulmonary multiple drug resistant tuberculosis |
title_short |
Hepatotoxic reactions during treatment of newly diagnosed patients with pulmonary multiple drug resistant tuberculosis |
title_full |
Hepatotoxic reactions during treatment of newly diagnosed patients with pulmonary multiple drug resistant tuberculosis |
title_fullStr |
Hepatotoxic reactions during treatment of newly diagnosed patients with pulmonary multiple drug resistant tuberculosis |
title_full_unstemmed |
Hepatotoxic reactions during treatment of newly diagnosed patients with pulmonary multiple drug resistant tuberculosis |
title_sort |
hepatotoxic reactions during treatment of newly diagnosed patients with pulmonary multiple drug resistant tuberculosis |
publisher |
NEW TERRA Publishing House |
series |
Tuberkulez i Bolezni Lëgkih |
issn |
2075-1230 2542-1506 |
publishDate |
2019-08-01 |
description |
216 new pulmonary tuberculosis patients suffering from multiple drug resistance (MDR) were examined. The patients were divided into 2 groups. The first group consisted of 164 patients in whom when admitted to hospital, GeneXpert MTB/RIF was used to test the resistance of Mycobacterium tuberculosis (MTB) to rifampicin. Initially, patients in this group were treated with chemotherapy regimen 4 (pyrazinamide, kanamycin/amikacin/capreomycin, fluoroquinolones, cycloserine/terizidone, prothionamide, PAS). Group 2 included 97 patients. They all were treated with chemotherapy regimen 1 (isoniazid, rifampicin, pyrazinamide, ethambutol/streptomycin) before MDR was confirmed in them by sputum culture on solid media (in 2-3 months of treatment) after that treatment regimen was amended with re-registration for chemotherapy regimen 4. It was found out that hepatotoxic reactions in patients without initial abnormal liver function when prescribing chemotherapy regimen 4 occurred in 31.3% of cases and when initially using regimen 1 followed by switching to regimen 4 – in 87.8% of cases ( p < 0.001). In the course of treatment, the signs of liver damage in patients who initially received regimen 4 were more frequent in the first 2 months of treatment, whereas in patients treated initially with regimen 1 with subsequent switching to regimen 4 – during the first 4 months. In the overwhelming majority of cases, hepatotoxic reactions were mild in patients who initially received regimen 4 as well as in patients initially treated with regimen 1 followed by switching to regimen 4. However, severe hepatotoxic reactions were more often observed in patients from Group 2. |
topic |
newly detected tuberculosis multiple drug resistance hepatotoxic reactions chemotherapy |
url |
https://www.tibl-journal.com/jour/article/view/1311 |
work_keys_str_mv |
AT ryuabdullaev hepatotoxicreactionsduringtreatmentofnewlydiagnosedpatientswithpulmonarymultipledrugresistanttuberculosis AT ogkomissarova hepatotoxicreactionsduringtreatmentofnewlydiagnosedpatientswithpulmonarymultipledrugresistanttuberculosis AT eschumakova hepatotoxicreactionsduringtreatmentofnewlydiagnosedpatientswithpulmonarymultipledrugresistanttuberculosis AT vsodinets hepatotoxicreactionsduringtreatmentofnewlydiagnosedpatientswithpulmonarymultipledrugresistanttuberculosis AT aeergeshov hepatotoxicreactionsduringtreatmentofnewlydiagnosedpatientswithpulmonarymultipledrugresistanttuberculosis |
_version_ |
1721263964647587840 |